3 items3 sources1 stocks
Zacks-Nov 4, 01:01 PM
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Beats Revenue Estimates - Zacks Investment Research
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Beats Revenue Estimates - Zacks Investment Research(摘要待生成)
Yahoo Finance / Benzinga-Nov 8, 03:13 AM
Viridian Therapeutics Inc (VRDN) (Q3 2026) Earnings Call Highlights: Lumvoa's Strong Debut With ... - Yahoo Finance
Viridian said Lumvoa generated $24.7 million in net product revenue in its first quarter of launch. [[fact-kf7i1s7r8]] More than 100 patients had completed at least one infusion as of September 30. [[fact-g9jzs3h5u]] Cash, cash equivalents and marketable securities were just over $955 million at quarter-end. [[fact-qe3d8xzx2]] CMS assigned Lumvoa a permanent J-code effective January 1, 2027. [[fact-2mx8mpbyf]] The company provided no specific guidance for fourth-quarter patient additions or revenue. [[fact-5m7jb0kmt]]
The Motley Fool-Nov 4, 07:25 PM
Viridian (VRDN) Q3 2026 Earnings Call Transcript
Viridian (VRDN) Q3 2026 Earnings Call Transcript(摘要待生成)